Esomeprazole Magnesium Enteric-coated Dry Suspension Won the Bid for National Centralized Drug Procurement


Release time:

2023-11-09

Zhejiang Erying Pharmaceutical Co., Ltd., a holding subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., participated in the bid for the ninth batch of national drug centralized procurement organized by the State Organization Drug Centralized Procurement and Use Joint Procurement Office. After the bid opening and evaluation by the joint procurement office, esomeprazole magnesium enteric-coated dry suspension (specification: 40mg) of Erying drug is proposed to win the bid for this centralized procurement.

On November 6, 2023, Zhejiang Erying Pharmaceutical Co., Ltd., a holding subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., participated in the bid for the ninth batch of national drug centralized procurement organized by the State Organization Drug Centralized Procurement and Use Joint Procurement Office. After the bid opening and evaluation by the joint procurement office, esomeprazole magnesium enteric-coated dry suspension (specification: 40mg) of Erying drug is proposed to win the bid for this centralized procurement.

Esomeprazole magnesium is the first proton pump inhibitor developed by AstraZeneca with a single optical isomer, the S-isomer of omeprazole, which blocks the final step of gastric acid secretion by specifically inhibiting H -K-ATPase in gastric parietal cells. Esomeprazole has the same pharmacological effect as omeprazole. Esomeprazole is more effective than omeprazole because of its slow metabolism, long maintenance time and high blood concentration.

Esomeprazole magnesium dry suspension applied for by Erying was approved by the State Drug Administration in January 2023, making it the first imitation in China. According to the regulations, the quality and efficacy of generic drugs are evaluated for consistency. Compared with other dosage forms, this product is suitable for all patients with dysphagia, such as patients with esophageal structural abnormalities, esophageal motor dysfunction characterized by dysphagia and other functional dysphagia, and elderly patients with dysphagia. At the same time, a nasogastric tube can be used, which is especially convenient for patients with nasal or gastric tubes.

This centralized procurement is the ninth batch of centralized drug procurement organized by the state. During the procurement cycle, medical institutions will give priority to the selected drugs in this centralized drug procurement and ensure the completion of the agreed procurement volume. If the company subsequently signs a purchase contract and implements it, it will help expand the sales scale of the product and increase market share. This product is also the first drug listed since the establishment of Erying drugs, which plays a vital role in the development of the company.